John Gribben, MD, DSc, FRCP, FRCPath, FMedSci, Barts Cancer Institute, London, UK shares key study data to lookout for at ASH 2020. Early trials for many novel agents in both acute myeloid leukemia (AML) and multiple myeloma will be presented. Of particular interest to Prof. Gribben is the upcoming results of trials in follicular lymphoma, such as bispecific antibodies and CD19 CAR-T cells. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Major study data to look out for from ASH 2020
Теги
Speaker: John GribbenInstitution: Barts Cancer InstituteEvent: VJVirtualEvent: ASH 2020Format: InterviewSubject: Multiple MyelomaTrial: ZUMA-5Trial: ELARATrial: APOLLOField: Perspectivesbispecific antibodiesNCT03105336NCT03180736Subject: LymphomaSubject: LeukemiaSubject: Follicular LymphomaSubject: Acute Myeloid LeukemiaSubject: Non-Hodgkin LymphomaField: CAR-T & Cellular TherapyField: Immuno-OncologyMedicines: Tisagenlecleucel
![#846 Felix als Rasenmäher - [Deutsch lernen durch Hören] @DldH Deutsch lernen mit Geschichten #dldh](https://s2.save4k.org/pic/vDsBRkLP2g8/mqdefault.jpg)
